SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19Plain-Language Summary
Rationale & Objective: A number of serologic tests for immunoglobulin G (IgG) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now commercially available, including multiple lateral flow immunoassays (LFIAs), which have the advantage of being inexpensive and easy to u...
Main Authors: | Maria Prendecki, Candice Clarke, Tom McKinnon, Liz Lightstone, Matthew C. Pickering, David C. Thomas, Stephen P. McAdoo, Michelle Willicombe |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Kidney Medicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590059520302533 |
Similar Items
-
Development of a Lateral Flow Immunoassay (LFIA) to Screen for the Release of the Endocrine Disruptor Bisphenol A from Polymer Materials and Products
by: Anna Raysyan, et al.
Published: (2021-07-01) -
Six decades of lateral flow immunoassay: from determining metabolic markers to diagnosing COVID-19
by: Boris G. Andryukov
Published: (2020-09-01) -
Lipid–Polymer Hybrids Encapsulating Iron-Oxide Nanoparticles as a Label for Lateral Flow Immunoassays
by: Shayesteh Bazsefidpar, et al.
Published: (2021-07-01) -
Catalytic lateral flow immunoassays (cLFIA™): Amplified signal in a self-contained assay format
by: Shawn P. Mulvaney, et al.
Published: (2020-12-01) -
Optimising effective parameters to improve performance quality in lateral flow immunoassay for detection of PBP2a in methicillin-resistant Staphylococcus aureus (MRSA)
by: M. Amini, et al.
Published: (2020-01-01)